Gilead Sciences: ‘Continued Dominance’

UBS analyst Matthew Roden considers new hepatitis-C data from Gilead Sciences (GILD) contained in an abstract for the American Association for the Study of Liver Diseases conference, and comes away convinced of Gilead’s continued dominance even in the face of competition from Merck (MRK), AbbVie (ABBV) and others: Eric Risberg/AP We find the 89% SVR4 […]